Bluebee

White paper: Bluebee Data security and compliance

Bluebee offers a global bio-informatics platform to process, analyze, share and store genomics data. With a private cloud service, Bluebee supports users in clinical diagnostics, therapeutics and research with advanced analytics for genomic data driven medicine. Designed for cross-functional teams of clinicians and life science researchers the Bluebee platform effectively centralizes and manages genomics data processes and storage. Bluebee’s multi-layered …

TCS Digital AI

AI in Pharmacovigilance — Re-imagining the ICSR processing

Over the last few decades, we have seen a spurt of medicines approved by regulatory authorities which have necessitated an increase in the need for monitoring drugs. Pharmacovigilance, is an arm of medical science which deals with gathering, monitoring and assessing the safety of drugs. It has gained increased focus and prominence, over the last decade. It’s thus not a …

Zenith Case Study

Case study: MES Centre of Excellence

The Challenge A global pharmaceutical company with sites worldwide had a requirement to standardise their Manufacturing Execution Systems across four sites. In order to achieve this they wanted to create an MES Centre of Excellence (CoE) that would sit above all sites and provide leadership, best practices, research, support and training. The CoE needed to be tailored to the customer’s …

Zenith Serialisation Whitepaper

Overcoming the practical challenges of Pharmaceutical Serialization

Is Pharmaceutical Serialization on your radar? With new regulations either being implemented or pending should it be? Serialization entails adding a unique identifier to single saleable units of prescription and some other medicines so they can be tracked and authenticated throughout the supply chain. Requirements for serialization are already active in some parts of the world and they will be …

lexisnexis whitepaper

Download whitepaper – Pharmaceutical & Life sciences: Third Party Due Diligence

Whitepaper by LexisNexis Few industries are as exposed to risk as the pharmaceuticals and life sciences. It is no longer enough to carry out basic checks alone on third-parties. Companies must engage in enhanced due diligence if they are to avoid the large fines and regulatory penalties. Effective third-party due diligence is increasingly recognized as a strategic driver for sustainable …

Sparking innovation with suppliers

WHITEPAPER by: Giles Breault, Principal and co-founder of The Beyond Group. Sammy Rashed, Principal and co-founder of The Beyond Group.  For some time now we have been delving into the question of what procurement teams imagine themselves becoming. The question may seem sophomoric on the surface but there are plenty of indicators that the same old results will no longer earn you a seat …

What Kim Kardashian Can Teach Pharma About Marketing?

Celebrity eccentricities aside, Kim Kardashian’s recent endorsement of the morning sickness drug, Diclegis, has shed new light on how to do marketing. The paid endorsement by the celebrity shows how effective social media can be for pharma. The reality star has over 40 million Instagram followers, and the post about Diclegis received over 450,000 likes and 10,000 comments. The manufacturer …

AGT, Advanced Granulation Technology, Pharma, Thermo Fisher

Download: Advanced Granulation Technology™ (AGT™ dry media format) Culture Media Benefits and Case Studies

This White Paper by Thermo Fisher Scientific, gives an overview of the decision factors that end-users consider when evaluating dry powder media vs. AGT™ dry media format, and summarizes situations where AGT™ dry media format may provide specific benefits over alternatives. It offers a review of how switching can address the problems inherent in dry powder media preparation and usage. The three case studies …

Pharmaceutical executives challenges

The Transformation Challenges Facing Pharmaceutical Executives

Pharmaceutical companies across the globe face unprecedented challenges as revenue streams come under pressure. This is a consequence of pricing pressures caused by healthcare reforms and government austerity measures. At the same time, companies face increased competition and the difficulty of bringing new drugs and products to market. They have to embrace technological innovation and look at cross-industry best practices …

benefit risk, quantification, pharma, Drug Safety

Implementing benefit-risk thinking and quantification into the culture and processes of a large pharmaceutical company.

At the 2014 World Drug Safety Congress Americas Susan Duke, GSK, gave a presentation on “Implementing benefit-risk thinking and quantification into the culture and processes of a large pharmaceutical company.” Download and learn: Benefit-Risk thinking and quantitative evaluation at GSK How it began Where we are now Keeping it simple (unless it’s complex) What are the right questions? Where is …